Company intelligence / Profile preview

Q32 Bio

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

ADX-097 (humanized anti-C3d mAb fusion protein): completed Phase 1 clinical trial (healthy volunteers), planning Phase 2 for renal and complement-mediated diseases (e.g., lupus nephritis, IgA nephropathy, C3 glomerulopathy, AAV). Bempikibart (ADX-914): fully human anti–interleukin-7 receptor alpha antagonist mAb, in Phase 2 for atopic dermatitis and alopecia areata.

Therapeutic areas: NephrologyImmunologyOphthalmologyDermatology
Modalities: Monoclonal antibodyMonoclonal antibody fusion proteinNanobodyBiologic
Industry: Biotech

Partnerships

CU InnovationsHomology Medicines (merger, drug/platform development/clinical advancement partnership)

Beyond the preview

Go deeper on Q32 Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q32 Bio.

Explore the full profile